Chemoradiation for adenocarcinoma of the anus

Michael Papagikos, Christopher H. Crane, John Skibber, Nora A. Janjan, Barry Feig, Miguel A. Rodriguez-Bigas, Arthur Hung, Robert A. Wolff, Marc Delclos, Edward Lin, Karen Cleary

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Purpose: To assess the efficacy and limitations of definitive chemoradiation for adenocarcinoma of the anal canal and to propose a treatment strategy that addresses the limitations of treatment. Methods and Materials: Between 1976 and 1998, 16 patients with localized adenocarcinoma of the anal canal were treated with radiotherapy with or without chemotherapy with curative intent. Available histologic slides were reviewed for evidence of primary adenocarcinoma of anal duct origin. The treatment results for these patients were compared with those of a group of patients with epidermoid histologic features who were all treated with definitive chemoradiation (55 Gy with concurrent 5-fluorouracil and cisplatin, n = 92) between 1989 and 1998. The hospital records were reviewed for all patients. Patients with epidermoid carcinoma presented with more advanced primary tumors (42% vs. 19% Stage T3 or greater). All adenocarcinoma patients were treated with radiotherapy (median dose 55 Gy): 11 received concurrent 5-fluorouracil-based chemotherapy and 5 received radiotherapy alone. The initial surgical procedures included abdominoperineal resection, excisional biopsies (n = 5), and local excision (n = 1). Abdominoperineal resection was performed as salvage therapy after local recurrence in 5 patients. The Kaplan-Meier method was used to calculate 5-year actuarial pelvic control, distant disease control, disease-free survival, and overall survival. The median follow-up was 45 months (range 5-196) for patients with adenocarcinoma and 44 months (range 9-115) for patients with epidermoid histologic features. Results: Both local and distant recurrence rates were significantly greater in the adenocarcinoma patients. Of 16 patients with adenocarcinoma, 7 (5-year actuarial rate 54%) had recurrence at the primary site compared with 16 (5-year actuarial rate 18%) of 92 patients with epidermoid histologic features (p = 0.004). Distant disease developed in more patients with adenocarcinoma (5-year actuarial rate 66%) than in patients with epidermoid carcinoma (5-year actuarial rate 10%, p

Original languageEnglish (US)
Pages (from-to)669-678
Number of pages10
JournalInternational Journal of Radiation Oncology Biology Physics
Volume55
Issue number3
DOIs
StatePublished - Mar 1 2003
Externally publishedYes

Fingerprint

Anal Canal
Adenocarcinoma
radiation therapy
canals
Radiotherapy
chemotherapy
Recurrence
Fluorouracil
Squamous Cell Carcinoma
cancer
Drug Therapy
Salvage Therapy
Hospital Records
ducts
chutes
Cisplatin
Disease-Free Survival
therapy
Therapeutics
tumors

Keywords

  • Adenocarcinoma
  • Anal cancer
  • Chemoradiation
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Papagikos, M., Crane, C. H., Skibber, J., Janjan, N. A., Feig, B., Rodriguez-Bigas, M. A., ... Cleary, K. (2003). Chemoradiation for adenocarcinoma of the anus. International Journal of Radiation Oncology Biology Physics, 55(3), 669-678. https://doi.org/10.1016/S0360-3016(02)04118-4

Chemoradiation for adenocarcinoma of the anus. / Papagikos, Michael; Crane, Christopher H.; Skibber, John; Janjan, Nora A.; Feig, Barry; Rodriguez-Bigas, Miguel A.; Hung, Arthur; Wolff, Robert A.; Delclos, Marc; Lin, Edward; Cleary, Karen.

In: International Journal of Radiation Oncology Biology Physics, Vol. 55, No. 3, 01.03.2003, p. 669-678.

Research output: Contribution to journalArticle

Papagikos, M, Crane, CH, Skibber, J, Janjan, NA, Feig, B, Rodriguez-Bigas, MA, Hung, A, Wolff, RA, Delclos, M, Lin, E & Cleary, K 2003, 'Chemoradiation for adenocarcinoma of the anus', International Journal of Radiation Oncology Biology Physics, vol. 55, no. 3, pp. 669-678. https://doi.org/10.1016/S0360-3016(02)04118-4
Papagikos M, Crane CH, Skibber J, Janjan NA, Feig B, Rodriguez-Bigas MA et al. Chemoradiation for adenocarcinoma of the anus. International Journal of Radiation Oncology Biology Physics. 2003 Mar 1;55(3):669-678. https://doi.org/10.1016/S0360-3016(02)04118-4
Papagikos, Michael ; Crane, Christopher H. ; Skibber, John ; Janjan, Nora A. ; Feig, Barry ; Rodriguez-Bigas, Miguel A. ; Hung, Arthur ; Wolff, Robert A. ; Delclos, Marc ; Lin, Edward ; Cleary, Karen. / Chemoradiation for adenocarcinoma of the anus. In: International Journal of Radiation Oncology Biology Physics. 2003 ; Vol. 55, No. 3. pp. 669-678.
@article{c0d38b9817844c07bbe9ba5f35d97ff4,
title = "Chemoradiation for adenocarcinoma of the anus",
abstract = "Purpose: To assess the efficacy and limitations of definitive chemoradiation for adenocarcinoma of the anal canal and to propose a treatment strategy that addresses the limitations of treatment. Methods and Materials: Between 1976 and 1998, 16 patients with localized adenocarcinoma of the anal canal were treated with radiotherapy with or without chemotherapy with curative intent. Available histologic slides were reviewed for evidence of primary adenocarcinoma of anal duct origin. The treatment results for these patients were compared with those of a group of patients with epidermoid histologic features who were all treated with definitive chemoradiation (55 Gy with concurrent 5-fluorouracil and cisplatin, n = 92) between 1989 and 1998. The hospital records were reviewed for all patients. Patients with epidermoid carcinoma presented with more advanced primary tumors (42{\%} vs. 19{\%} Stage T3 or greater). All adenocarcinoma patients were treated with radiotherapy (median dose 55 Gy): 11 received concurrent 5-fluorouracil-based chemotherapy and 5 received radiotherapy alone. The initial surgical procedures included abdominoperineal resection, excisional biopsies (n = 5), and local excision (n = 1). Abdominoperineal resection was performed as salvage therapy after local recurrence in 5 patients. The Kaplan-Meier method was used to calculate 5-year actuarial pelvic control, distant disease control, disease-free survival, and overall survival. The median follow-up was 45 months (range 5-196) for patients with adenocarcinoma and 44 months (range 9-115) for patients with epidermoid histologic features. Results: Both local and distant recurrence rates were significantly greater in the adenocarcinoma patients. Of 16 patients with adenocarcinoma, 7 (5-year actuarial rate 54{\%}) had recurrence at the primary site compared with 16 (5-year actuarial rate 18{\%}) of 92 patients with epidermoid histologic features (p = 0.004). Distant disease developed in more patients with adenocarcinoma (5-year actuarial rate 66{\%}) than in patients with epidermoid carcinoma (5-year actuarial rate 10{\%}, p",
keywords = "Adenocarcinoma, Anal cancer, Chemoradiation, Radiotherapy",
author = "Michael Papagikos and Crane, {Christopher H.} and John Skibber and Janjan, {Nora A.} and Barry Feig and Rodriguez-Bigas, {Miguel A.} and Arthur Hung and Wolff, {Robert A.} and Marc Delclos and Edward Lin and Karen Cleary",
year = "2003",
month = "3",
day = "1",
doi = "10.1016/S0360-3016(02)04118-4",
language = "English (US)",
volume = "55",
pages = "669--678",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Chemoradiation for adenocarcinoma of the anus

AU - Papagikos, Michael

AU - Crane, Christopher H.

AU - Skibber, John

AU - Janjan, Nora A.

AU - Feig, Barry

AU - Rodriguez-Bigas, Miguel A.

AU - Hung, Arthur

AU - Wolff, Robert A.

AU - Delclos, Marc

AU - Lin, Edward

AU - Cleary, Karen

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Purpose: To assess the efficacy and limitations of definitive chemoradiation for adenocarcinoma of the anal canal and to propose a treatment strategy that addresses the limitations of treatment. Methods and Materials: Between 1976 and 1998, 16 patients with localized adenocarcinoma of the anal canal were treated with radiotherapy with or without chemotherapy with curative intent. Available histologic slides were reviewed for evidence of primary adenocarcinoma of anal duct origin. The treatment results for these patients were compared with those of a group of patients with epidermoid histologic features who were all treated with definitive chemoradiation (55 Gy with concurrent 5-fluorouracil and cisplatin, n = 92) between 1989 and 1998. The hospital records were reviewed for all patients. Patients with epidermoid carcinoma presented with more advanced primary tumors (42% vs. 19% Stage T3 or greater). All adenocarcinoma patients were treated with radiotherapy (median dose 55 Gy): 11 received concurrent 5-fluorouracil-based chemotherapy and 5 received radiotherapy alone. The initial surgical procedures included abdominoperineal resection, excisional biopsies (n = 5), and local excision (n = 1). Abdominoperineal resection was performed as salvage therapy after local recurrence in 5 patients. The Kaplan-Meier method was used to calculate 5-year actuarial pelvic control, distant disease control, disease-free survival, and overall survival. The median follow-up was 45 months (range 5-196) for patients with adenocarcinoma and 44 months (range 9-115) for patients with epidermoid histologic features. Results: Both local and distant recurrence rates were significantly greater in the adenocarcinoma patients. Of 16 patients with adenocarcinoma, 7 (5-year actuarial rate 54%) had recurrence at the primary site compared with 16 (5-year actuarial rate 18%) of 92 patients with epidermoid histologic features (p = 0.004). Distant disease developed in more patients with adenocarcinoma (5-year actuarial rate 66%) than in patients with epidermoid carcinoma (5-year actuarial rate 10%, p

AB - Purpose: To assess the efficacy and limitations of definitive chemoradiation for adenocarcinoma of the anal canal and to propose a treatment strategy that addresses the limitations of treatment. Methods and Materials: Between 1976 and 1998, 16 patients with localized adenocarcinoma of the anal canal were treated with radiotherapy with or without chemotherapy with curative intent. Available histologic slides were reviewed for evidence of primary adenocarcinoma of anal duct origin. The treatment results for these patients were compared with those of a group of patients with epidermoid histologic features who were all treated with definitive chemoradiation (55 Gy with concurrent 5-fluorouracil and cisplatin, n = 92) between 1989 and 1998. The hospital records were reviewed for all patients. Patients with epidermoid carcinoma presented with more advanced primary tumors (42% vs. 19% Stage T3 or greater). All adenocarcinoma patients were treated with radiotherapy (median dose 55 Gy): 11 received concurrent 5-fluorouracil-based chemotherapy and 5 received radiotherapy alone. The initial surgical procedures included abdominoperineal resection, excisional biopsies (n = 5), and local excision (n = 1). Abdominoperineal resection was performed as salvage therapy after local recurrence in 5 patients. The Kaplan-Meier method was used to calculate 5-year actuarial pelvic control, distant disease control, disease-free survival, and overall survival. The median follow-up was 45 months (range 5-196) for patients with adenocarcinoma and 44 months (range 9-115) for patients with epidermoid histologic features. Results: Both local and distant recurrence rates were significantly greater in the adenocarcinoma patients. Of 16 patients with adenocarcinoma, 7 (5-year actuarial rate 54%) had recurrence at the primary site compared with 16 (5-year actuarial rate 18%) of 92 patients with epidermoid histologic features (p = 0.004). Distant disease developed in more patients with adenocarcinoma (5-year actuarial rate 66%) than in patients with epidermoid carcinoma (5-year actuarial rate 10%, p

KW - Adenocarcinoma

KW - Anal cancer

KW - Chemoradiation

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=0037361252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037361252&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(02)04118-4

DO - 10.1016/S0360-3016(02)04118-4

M3 - Article

VL - 55

SP - 669

EP - 678

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -